Search bioRxiv⌕ Search

Biology subjects

Fernagut, P.-O.

Publications and source records attributed to Fernagut, P.-O..

3 recordsLinked to original sources

miR-10a-5p as a critical molecular regulator of dopaminergic impulsivity in the nucleus accumbens

Impulsive-compulsive disorders (ICDs), including pathological gambling, hypersexuality, and compulsive buying, are frequently precipitated by dopamine D2/3 receptor agonists such as pramipexole (PPX), yet the molecular mechanisms that confer individual vulnerability remain poorly understood. Impulsive choice, a core dimension of ICDs, is modulated by dopaminergic signaling within corticostriatal circuits, but the microRNAs (miRs) that potentially translate this signaling into persistent behavioral change have not been identified. Here, we combined a delay discounting task (DDT) with high-throughput miR sequencing in the dorsal striatum and nucleus accumbens (NAcc) of rats stratified by baseline impulsivity and subchronic PPX treatment. PPX increased impulsive choice selectively in low- and mid-impulsive rats, whereas high-impulsive rats remained unaffected, consistent with a ceiling effect. Among the differentially expressed miRs, miR-10a-5p emerged as the strongest candidate: it was constitutively elevated in high-impulsive rats and upregulated by PPX in low- and mid-impulsive animals in both regions, thereby paralleling the trait-dependent behavioral effect of the drug. In vivo viral-mediated overexpression of miR-10a-5p confirmed its predicted downregulation of the PI3K-AKT-mTOR and BDNF pathways in the striatum, and, critically, overexpression restricted to the NAcc, but not the dorsal striatum, was sufficient to increase impulsive choice, recapitulating the pro-impulsive effect of PPX. These findings identify miR-10a-5p as a critical molecular regulator of impulsivity through its activity in the NAcc, providing a mechanistic link between dopaminergic perturbation, trait vulnerability, and ICDs, and opening new avenues for the development of miR-directed therapeutic strategies for these disorders.

neuroscience↗

Alpha-synuclein-induced nigrostriatal degeneration and pramipexole treatment disrupt frontostriatal plasticity

BACKGROUNDParkinsons disease is characterized by the degeneration of substantia nigra pars compacta (SNc) dopaminergic neurons, leading to motor and cognitive symptoms. Numerous cellular and molecular adaptations due to the degenerative process or dopamine replacement therapy (DRT) have been described in motor networks but little is known regarding associative basal ganglia loops. OBJECTIVETo investigate the contributions of nigrostriatal degeneration and pramipexole (PPX) on neuronal activity in the orbitofrontal cortex (OFC), frontostriatal plasticity and markers of synaptic plasticity. METHODSBilateral nigrostriatal degeneration was induced by viral-mediated overexpression of human mutated alpha-synuclein in the SNc. Juxtacellular recordings were performed in anesthetized rats to evaluate neuronal activity in the OFC. Recordings in the dorsomedial striatum (DMS) were performed and spike probability in response to OFC stimulation was measured before and after a high frequency stimulation (HFS). Post-mortem analysis included stereological assessment of nigral neurodegeneration, BDNF and TrkB levels. RESULTSNigrostriatal neurodegeneration led to altered firing patterns of OFC neurons that were restored by PPX. HFS of the OFC led to an increased spike probability in the DMS, while dopaminergic loss had an opposite effect. PPX led to a decreased spike probability following HFS in control rats and failed to counteract the effect of dopaminergic neurodegeneration. These alterations were associated with decreased levels of BDNF and TrkB. CONCLUSIONSBoth nigral dopaminergic loss and PPX concur to alter fronstostriatal transmission, precluding adequate information processing in associative basal ganglia loops as a gateway for the development of non-motor symptoms or non-motor side-effects of DRT.

neuroscience↗

Premorbid performances determine the deleterious effects of nigrostriatal degeneration and pramipexole on behavioural flexibility

Subtle cognitive impairment can occur early in the course of Parkinsons disease (PD) and may manifest under different forms of executive dysfunction such as impaired cognitive flexibility. The precise contribution of nigrostriatal dopaminergic neurodegeneration to these non-motor features of the disease is poorly known. Whether such cognitive impairment associated with the disease process may also predate and contribute to the development of neuropsychiatric side-effects following dopamine replacement therapy remains largely unknown. To address these issues, we investigated the respective contributions of nigrostriatal degeneration and chronic treatment with the dopamine D3-preferring agonist pramipexole on behavioural flexibility in a rat model of PD. Flexible, intermediate and inflexible rats were identified based on baseline assessment of behavioural flexibility using an operant set-shifting task. Nigrostriatal degeneration was induced by bilateral viral-mediated expression of A53T mutated human -synuclein in the substantia nigra pars compacta and behavioural flexibility was assessed after induction of nigrostriatal degeneration, and during chronic pramipexole treatment. Nigrostriatal degeneration impaired behavioural flexibility in flexible but not in inflexible rats. Pramipexole induced a decrease of behavioural flexibility that was exacerbated in lesioned rats and in the most flexible individuals. Furthermore, the deficits induced by pramipexole in lesioned rats affected different components of the task between flexible and inflexible individuals. This study demonstrates that nigrostriatal degeneration and pramipexole unequally impair behavioural flexibility, suggesting that the susceptibility to develop non-motor impairments upon treatment initiation could primarily depend on premorbid differences in behavioural flexibility.

neuroscience↗